Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final - Hurler–Scheie syndrome - Document - PDFSEARCH.IO

First Page		Document Content
BioMarin Pharmaceutical Rare diseases Orphan drugs Lysosomal storage diseases Glycogen storage disease type II Mucopolysaccharidosis Mannose 6-phosphate Hurler syndrome Phenylketonuria Health Medicine Genetic genealogy		Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final Add to Reading List Source URL: www.apjohnventures.com Download Document from Source Website File Size: 59,18 KB Share Document on Facebook

	Implantação de um protocolo laboratorial para o diagnóstico de Mucopolissacaridoses VI e VII* Evaluation of a laboratorial protocol for Mucopolysaccharidosis VI and VII Gustavo Monteiro VIANA1; Camila de Britto Ponte DocID: 1v8Z4 - View Document
	What is HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive DocID: 1lIxr - View Document
	MUCOPOLYSACCHARIDOSES Rare Diseases Unit of the Finnish Association of People with Physical Disabilities Support for this guide was provided by Genzyme. DocID: 1fJSQ - View Document
	May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im DocID: 1aiEg - View Document
	Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final DocID: 19Qom - View Document